AI-Driven Drug Discovery: Unravelling Biological Complexities
, Director, Digital Biology, NVIDIA
, Founder and Chief Executive Officer, Odyssey Therapeutics
, Founder and Chief Executive Officer, Adjunct Professor of Computer Science, Insitro, Stanford University
, Chief Scientific Officer, Relation Therapeutics
, Co-Founder and Chief Technology Officer, VantAI
Exploring the intersection of biology and artificial intelligence, this panel will delve into the transformative role of AI, from graph machine learning to large language models, in drug discovery. Renowned experts will discuss the acceleration of in silico experiments, the challenges, and the role of generative AI in creating novel biological structures. We aim to not only bridge the gap between biologists and computer scientists, but also offer insights into the potential of integrating large-scale computational methods for advancements in drug development.